| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhabdomyosarcoma | 28 | 2024 | 342 | 8.690 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 14 | 2024 | 76 | 5.140 |
Why?
|
| Hepatoblastoma | 12 | 2019 | 225 | 3.750 |
Why?
|
| Soft Tissue Neoplasms | 10 | 2024 | 917 | 2.280 |
Why?
|
| Child | 98 | 2024 | 30366 | 2.170 |
Why?
|
| Child, Preschool | 55 | 2024 | 16925 | 1.850 |
Why?
|
| Infant | 49 | 2024 | 13873 | 1.820 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2024 | 10352 | 1.800 |
Why?
|
| Adolescent | 63 | 2024 | 32534 | 1.540 |
Why?
|
| Denosumab | 2 | 2021 | 72 | 1.430 |
Why?
|
| Bone Density Conservation Agents | 3 | 2021 | 205 | 1.390 |
Why?
|
| Nasopharyngeal Neoplasms | 3 | 2018 | 337 | 1.360 |
Why?
|
| Sarcoma | 8 | 2024 | 1839 | 1.350 |
Why?
|
| Wilms Tumor | 5 | 2023 | 297 | 1.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2024 | 16600 | 1.330 |
Why?
|
| Bone Neoplasms | 6 | 2024 | 2667 | 1.250 |
Why?
|
| Neoplasms, Muscle Tissue | 2 | 2021 | 23 | 1.210 |
Why?
|
| Lung Diseases | 4 | 2014 | 753 | 1.190 |
Why?
|
| Neuroendocrine Tumors | 3 | 2024 | 651 | 1.160 |
Why?
|
| Kidney Neoplasms | 8 | 2023 | 3146 | 1.100 |
Why?
|
| Prognosis | 37 | 2024 | 22462 | 1.090 |
Why?
|
| Histiocytosis, Langerhans-Cell | 3 | 2014 | 284 | 1.070 |
Why?
|
| Vincristine | 5 | 2024 | 1572 | 1.070 |
Why?
|
| Liver Neoplasms | 12 | 2019 | 4795 | 1.060 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 5 | 2023 | 64 | 1.020 |
Why?
|
| Cyclophosphamide | 7 | 2024 | 3231 | 1.000 |
Why?
|
| Humans | 125 | 2024 | 270832 | 0.990 |
Why?
|
| Male | 75 | 2024 | 128425 | 0.980 |
Why?
|
| Sarcoma, Synovial | 2 | 2024 | 130 | 0.930 |
Why?
|
| Pulmonary Blastoma | 2 | 2015 | 21 | 0.930 |
Why?
|
| Female | 78 | 2024 | 148552 | 0.900 |
Why?
|
| Thoracic Wall | 2 | 2023 | 188 | 0.890 |
Why?
|
| Combined Modality Therapy | 14 | 2024 | 9041 | 0.880 |
Why?
|
| Myofibroma | 2 | 2020 | 12 | 0.880 |
Why?
|
| Follow-Up Studies | 23 | 2024 | 15241 | 0.870 |
Why?
|
| Granuloma, Giant Cell | 2 | 2020 | 17 | 0.870 |
Why?
|
| Young Adult | 28 | 2024 | 22052 | 0.850 |
Why?
|
| Oncogene Proteins, Fusion | 6 | 2021 | 801 | 0.830 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2015 | 741 | 0.820 |
Why?
|
| Sirolimus | 3 | 2024 | 831 | 0.810 |
Why?
|
| Thyroid Neoplasms | 4 | 2021 | 1882 | 0.800 |
Why?
|
| Biliary Tract | 1 | 2021 | 36 | 0.790 |
Why?
|
| Osteolysis, Essential | 2 | 2012 | 8 | 0.790 |
Why?
|
| Puberty, Precocious | 2 | 2019 | 28 | 0.780 |
Why?
|
| Melanosis | 1 | 2021 | 16 | 0.750 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2021 | 17 | 0.750 |
Why?
|
| Myofibromatosis | 1 | 2020 | 7 | 0.740 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2021 | 53 | 0.740 |
Why?
|
| Infant, Newborn | 19 | 2022 | 8580 | 0.730 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2020 | 39 | 0.720 |
Why?
|
| Papilloma | 1 | 2020 | 88 | 0.720 |
Why?
|
| Bevacizumab | 3 | 2020 | 957 | 0.720 |
Why?
|
| Cyclin B | 1 | 2019 | 69 | 0.690 |
Why?
|
| Aicardi Syndrome | 1 | 2019 | 17 | 0.690 |
Why?
|
| Quinolines | 3 | 2021 | 402 | 0.690 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 1335 | 0.690 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2019 | 36 | 0.690 |
Why?
|
| Survival Rate | 20 | 2024 | 12516 | 0.690 |
Why?
|
| Carcinoma, Papillary | 2 | 2020 | 580 | 0.680 |
Why?
|
| Phenylurea Compounds | 3 | 2021 | 600 | 0.680 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2019 | 43 | 0.680 |
Why?
|
| Lung | 4 | 2015 | 3270 | 0.680 |
Why?
|
| Ependymoma | 2 | 2013 | 269 | 0.670 |
Why?
|
| Leydig Cell Tumor | 1 | 2019 | 9 | 0.660 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2020 | 131 | 0.650 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 2015 | 145 | 0.650 |
Why?
|
| Retrospective Studies | 30 | 2024 | 39703 | 0.650 |
Why?
|
| GTP Phosphohydrolases | 1 | 2021 | 340 | 0.640 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2021 | 179 | 0.630 |
Why?
|
| Registries | 5 | 2020 | 2238 | 0.620 |
Why?
|
| Bronchial Neoplasms | 1 | 2019 | 83 | 0.620 |
Why?
|
| Orchiectomy | 1 | 2019 | 226 | 0.620 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2018 | 49 | 0.620 |
Why?
|
| Neoplasms | 10 | 2022 | 15854 | 0.600 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 2 | 2016 | 102 | 0.590 |
Why?
|
| Femoral Neoplasms | 2 | 2015 | 66 | 0.580 |
Why?
|
| Granulosa Cell Tumor | 2 | 2018 | 81 | 0.570 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2018 | 75 | 0.570 |
Why?
|
| Rare Diseases | 1 | 2020 | 360 | 0.550 |
Why?
|
| Doxorubicin | 7 | 2023 | 3131 | 0.550 |
Why?
|
| Carcinoid Tumor | 1 | 2019 | 281 | 0.550 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 473 | 0.550 |
Why?
|
| Osteosarcoma | 3 | 2021 | 948 | 0.540 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 408 | 0.530 |
Why?
|
| Biomarkers, Tumor | 12 | 2023 | 10694 | 0.530 |
Why?
|
| Cough | 2 | 2014 | 126 | 0.530 |
Why?
|
| Bleomycin | 2 | 2014 | 470 | 0.520 |
Why?
|
| Medical Oncology | 4 | 2023 | 1462 | 0.520 |
Why?
|
| Hemangioendothelioma | 1 | 2015 | 35 | 0.510 |
Why?
|
| Bone Marrow | 1 | 2023 | 2431 | 0.510 |
Why?
|
| Repressor Proteins | 2 | 2022 | 1725 | 0.510 |
Why?
|
| Fertility Preservation | 1 | 2017 | 158 | 0.500 |
Why?
|
| Myositis | 1 | 2016 | 84 | 0.500 |
Why?
|
| Oncogene Proteins | 2 | 2014 | 370 | 0.500 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2015 | 113 | 0.500 |
Why?
|
| Eczema | 1 | 2014 | 34 | 0.480 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 554 | 0.480 |
Why?
|
| Lung Neoplasms | 7 | 2023 | 11774 | 0.480 |
Why?
|
| Nasal Cavity | 1 | 2015 | 146 | 0.480 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2015 | 115 | 0.480 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2015 | 254 | 0.470 |
Why?
|
| Chromosome Disorders | 2 | 2013 | 424 | 0.470 |
Why?
|
| Pituitary Gland | 1 | 2014 | 157 | 0.470 |
Why?
|
| Beckwith-Wiedemann Syndrome | 1 | 2014 | 38 | 0.470 |
Why?
|
| Adamantinoma | 1 | 2014 | 7 | 0.470 |
Why?
|
| Gene Fusion | 3 | 2022 | 214 | 0.460 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2022 | 2610 | 0.460 |
Why?
|
| Dyspnea | 2 | 2014 | 420 | 0.450 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 1011 | 0.440 |
Why?
|
| Rhabdoid Tumor | 1 | 2014 | 111 | 0.440 |
Why?
|
| Nose Neoplasms | 1 | 2015 | 236 | 0.440 |
Why?
|
| Research Report | 1 | 2014 | 143 | 0.440 |
Why?
|
| Tibia | 1 | 2014 | 127 | 0.440 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 1287 | 0.440 |
Why?
|
| Whole-Body Irradiation | 1 | 2014 | 324 | 0.430 |
Why?
|
| Survivors | 4 | 2015 | 1023 | 0.430 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 4838 | 0.430 |
Why?
|
| Ovarian Neoplasms | 3 | 2018 | 4774 | 0.420 |
Why?
|
| Melanoma | 2 | 2021 | 5525 | 0.420 |
Why?
|
| Treatment Outcome | 16 | 2024 | 33837 | 0.420 |
Why?
|
| Forkhead Box Protein O1 | 2 | 2024 | 166 | 0.410 |
Why?
|
| Disease-Free Survival | 10 | 2023 | 10249 | 0.400 |
Why?
|
| Dactinomycin | 2 | 2024 | 163 | 0.400 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 1009 | 0.400 |
Why?
|
| Splenic Diseases | 1 | 2012 | 59 | 0.400 |
Why?
|
| Antineoplastic Agents | 10 | 2021 | 14651 | 0.390 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 279 | 0.380 |
Why?
|
| Bone and Bones | 1 | 2014 | 612 | 0.380 |
Why?
|
| Adult | 24 | 2024 | 81579 | 0.370 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2018 | 3391 | 0.370 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2024 | 686 | 0.370 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2019 | 3972 | 0.370 |
Why?
|
| Lymphangioma | 1 | 2010 | 35 | 0.370 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 318 | 0.370 |
Why?
|
| Hepatectomy | 2 | 2014 | 1013 | 0.370 |
Why?
|
| Deoxycytidine | 1 | 2016 | 1377 | 0.370 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 609 | 0.360 |
Why?
|
| Supratentorial Neoplasms | 1 | 2011 | 79 | 0.360 |
Why?
|
| Neoadjuvant Therapy | 3 | 2023 | 5206 | 0.360 |
Why?
|
| Carboplatin | 1 | 2014 | 879 | 0.360 |
Why?
|
| Membrane Proteins | 1 | 2021 | 2957 | 0.350 |
Why?
|
| Salvage Therapy | 1 | 2018 | 2118 | 0.350 |
Why?
|
| Carcinoma | 3 | 2021 | 2619 | 0.350 |
Why?
|
| Necrosis | 1 | 2011 | 604 | 0.350 |
Why?
|
| Pleural Effusion | 1 | 2012 | 219 | 0.350 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 1346 | 0.340 |
Why?
|
| Clinical Trials as Topic | 6 | 2024 | 3852 | 0.340 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 531 | 0.330 |
Why?
|
| Disease Management | 3 | 2021 | 1111 | 0.320 |
Why?
|
| Watchful Waiting | 1 | 2011 | 292 | 0.320 |
Why?
|
| Brain Neoplasms | 3 | 2022 | 4981 | 0.320 |
Why?
|
| Respiratory Function Tests | 3 | 2014 | 354 | 0.310 |
Why?
|
| Ifosfamide | 3 | 2023 | 357 | 0.300 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2022 | 458 | 0.290 |
Why?
|
| Postoperative Care | 1 | 2011 | 731 | 0.280 |
Why?
|
| Remission Induction | 3 | 2019 | 3645 | 0.280 |
Why?
|
| Nuclear Proteins | 3 | 2018 | 3455 | 0.280 |
Why?
|
| Databases, Factual | 1 | 2014 | 2285 | 0.270 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 5234 | 0.270 |
Why?
|
| Thyroidectomy | 2 | 2020 | 492 | 0.270 |
Why?
|
| Risk Factors | 8 | 2022 | 17819 | 0.270 |
Why?
|
| Neoplasm Staging | 8 | 2023 | 13979 | 0.260 |
Why?
|
| Radionuclide Imaging | 2 | 2021 | 658 | 0.260 |
Why?
|
| Hodgkin Disease | 1 | 2014 | 1487 | 0.250 |
Why?
|
| Neoplasms, Second Primary | 2 | 2024 | 1379 | 0.240 |
Why?
|
| Perineum | 1 | 2024 | 116 | 0.230 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2021 | 2266 | 0.220 |
Why?
|
| Octreotide | 1 | 2024 | 132 | 0.220 |
Why?
|
| Organoplatinum Compounds | 3 | 2014 | 703 | 0.210 |
Why?
|
| Margins of Excision | 1 | 2024 | 314 | 0.210 |
Why?
|
| Anthracyclines | 2 | 2014 | 339 | 0.200 |
Why?
|
| Neuroblastoma | 2 | 2020 | 701 | 0.200 |
Why?
|
| Cohort Studies | 5 | 2024 | 9434 | 0.200 |
Why?
|
| Eyelids | 1 | 2023 | 155 | 0.200 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2021 | 8 | 0.200 |
Why?
|
| Intersectoral Collaboration | 1 | 2021 | 42 | 0.200 |
Why?
|
| Incidence | 5 | 2022 | 5838 | 0.200 |
Why?
|
| Iodine Radioisotopes | 2 | 2021 | 388 | 0.200 |
Why?
|
| alpha-Fetoproteins | 2 | 2013 | 256 | 0.190 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 312 | 0.190 |
Why?
|
| Dacarbazine | 2 | 2013 | 505 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 7786 | 0.190 |
Why?
|
| Radiotherapy Dosage | 3 | 2014 | 4003 | 0.190 |
Why?
|
| Receptors, Peptide | 1 | 2021 | 88 | 0.190 |
Why?
|
| Methotrexate | 2 | 2015 | 1027 | 0.180 |
Why?
|
| Camptothecin | 2 | 2013 | 538 | 0.180 |
Why?
|
| Orbital Neoplasms | 1 | 2023 | 238 | 0.180 |
Why?
|
| Sulfones | 1 | 2021 | 149 | 0.180 |
Why?
|
| Prospective Studies | 6 | 2024 | 13365 | 0.180 |
Why?
|
| Radioisotopes | 1 | 2021 | 177 | 0.180 |
Why?
|
| Induction Chemotherapy | 2 | 2020 | 671 | 0.180 |
Why?
|
| Anus Neoplasms | 1 | 2024 | 417 | 0.180 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 4888 | 0.180 |
Why?
|
| Texas | 4 | 2019 | 6412 | 0.170 |
Why?
|
| Global Burden of Disease | 1 | 2019 | 29 | 0.170 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 271 | 0.170 |
Why?
|
| Maximum Tolerated Dose | 2 | 2013 | 1323 | 0.170 |
Why?
|
| Foot Diseases | 1 | 2019 | 49 | 0.170 |
Why?
|
| Corpus Callosum | 1 | 2019 | 129 | 0.160 |
Why?
|
| Liposarcoma | 1 | 2021 | 247 | 0.160 |
Why?
|
| Liver Transplantation | 4 | 2019 | 1184 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 271 | 0.160 |
Why?
|
| Radiopharmaceuticals | 2 | 2021 | 1338 | 0.160 |
Why?
|
| Thigh | 1 | 2019 | 164 | 0.150 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2018 | 37 | 0.150 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2020 | 299 | 0.150 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2019 | 219 | 0.150 |
Why?
|
| DiGeorge Syndrome | 1 | 2018 | 80 | 0.150 |
Why?
|
| SEER Program | 2 | 2019 | 1044 | 0.150 |
Why?
|
| Mentoring | 1 | 2019 | 100 | 0.150 |
Why?
|
| Extremities | 1 | 2019 | 308 | 0.150 |
Why?
|
| Chemoradiotherapy | 2 | 2017 | 2029 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 770 | 0.140 |
Why?
|
| Trisomy 13 Syndrome | 2 | 2013 | 18 | 0.140 |
Why?
|
| Infant, Premature, Diseases | 1 | 2019 | 247 | 0.140 |
Why?
|
| Mentors | 1 | 2019 | 203 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2397 | 0.140 |
Why?
|
| Cisplatin | 2 | 2015 | 2496 | 0.140 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2021 | 499 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 676 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2019 | 309 | 0.140 |
Why?
|
| Biopsy | 2 | 2015 | 3543 | 0.140 |
Why?
|
| Bacterial Infections | 1 | 2020 | 507 | 0.140 |
Why?
|
| Hypertension, Malignant | 1 | 2016 | 5 | 0.140 |
Why?
|
| Laparotomy | 1 | 2017 | 228 | 0.130 |
Why?
|
| Thoracic Neoplasms | 1 | 2019 | 347 | 0.130 |
Why?
|
| Adrenocortical Adenoma | 1 | 2016 | 24 | 0.130 |
Why?
|
| Etoposide | 2 | 2021 | 905 | 0.130 |
Why?
|
| Renin | 1 | 2016 | 102 | 0.130 |
Why?
|
| Neutropenia | 1 | 2020 | 1001 | 0.130 |
Why?
|
| Carcinoma, Small Cell | 1 | 2018 | 425 | 0.130 |
Why?
|
| Trisomy | 2 | 2013 | 239 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2018 | 331 | 0.130 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2016 | 115 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 4962 | 0.130 |
Why?
|
| Ovariectomy | 1 | 2016 | 372 | 0.130 |
Why?
|
| Treatment Failure | 2 | 2020 | 1432 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2016 | 187 | 0.120 |
Why?
|
| Diabetes Insipidus | 1 | 2014 | 25 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2016 | 228 | 0.120 |
Why?
|
| Sacrum | 1 | 2015 | 139 | 0.120 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 226 | 0.120 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 1959 | 0.120 |
Why?
|
| Nephrectomy | 1 | 2019 | 808 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 1259 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 878 | 0.120 |
Why?
|
| Utah | 1 | 2014 | 48 | 0.120 |
Why?
|
| Recurrence | 3 | 2023 | 4882 | 0.120 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 1740 | 0.120 |
Why?
|
| Hepatic Veins | 1 | 2014 | 59 | 0.120 |
Why?
|
| Appendiceal Neoplasms | 1 | 2017 | 250 | 0.120 |
Why?
|
| Infant, Premature | 1 | 2019 | 826 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2019 | 605 | 0.110 |
Why?
|
| Vascular Neoplasms | 1 | 2014 | 113 | 0.110 |
Why?
|
| Carnitine | 1 | 2014 | 87 | 0.110 |
Why?
|
| Vena Cava, Inferior | 1 | 2014 | 195 | 0.110 |
Why?
|
| Diphosphonates | 1 | 2015 | 264 | 0.110 |
Why?
|
| Whole Body Imaging | 1 | 2014 | 113 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1209 | 0.110 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2016 | 242 | 0.110 |
Why?
|
| Actins | 1 | 2016 | 616 | 0.110 |
Why?
|
| Proportional Hazards Models | 4 | 2024 | 5087 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2018 | 496 | 0.110 |
Why?
|
| Demography | 1 | 2014 | 434 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 499 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2022 | 6831 | 0.100 |
Why?
|
| Melphalan | 1 | 2015 | 875 | 0.100 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 320 | 0.100 |
Why?
|
| Los Angeles | 1 | 2012 | 34 | 0.100 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2013 | 131 | 0.100 |
Why?
|
| Leucovorin | 1 | 2013 | 344 | 0.100 |
Why?
|
| Pyrimidines | 2 | 2023 | 3664 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 2198 | 0.100 |
Why?
|
| Mutation | 3 | 2021 | 15850 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2017 | 550 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 2020 | 1238 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2014 | 835 | 0.100 |
Why?
|
| Paired Box Transcription Factors | 2 | 2023 | 133 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1210 | 0.100 |
Why?
|
| Germ Cells | 2 | 2024 | 347 | 0.100 |
Why?
|
| Radiation Pneumonitis | 1 | 2013 | 313 | 0.090 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2014 | 460 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2024 | 6251 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2016 | 2034 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 1372 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 1991 | 0.090 |
Why?
|
| Quality of Life | 1 | 2024 | 4740 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2020 | 3067 | 0.090 |
Why?
|
| Imidazoles | 1 | 2015 | 1055 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 2483 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 7812 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2019 | 2165 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2020 | 4967 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 3646 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2315 | 0.080 |
Why?
|
| Genomics | 1 | 2020 | 2817 | 0.080 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 789 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 1885 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 1424 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2015 | 1858 | 0.080 |
Why?
|
| Liver | 2 | 2019 | 3122 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2017 | 1292 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2014 | 738 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2018 | 5489 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 2015 | 1472 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2020 | 2437 | 0.070 |
Why?
|
| Pneumonia | 1 | 2013 | 798 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2014 | 6031 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 5415 | 0.070 |
Why?
|
| Prevalence | 1 | 2014 | 3414 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 3343 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2015 | 6478 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 5099 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 4981 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2012 | 1732 | 0.060 |
Why?
|
| Age Factors | 1 | 2014 | 5486 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 2415 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 6187 | 0.060 |
Why?
|
| Inflammation | 1 | 2013 | 2525 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 2316 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 5975 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 5156 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2023 | 32 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2023 | 34 | 0.050 |
Why?
|
| Mediator Complex | 1 | 2023 | 62 | 0.050 |
Why?
|
| Nucleotides | 1 | 2023 | 174 | 0.050 |
Why?
|
| Disease Progression | 1 | 2014 | 6895 | 0.050 |
Why?
|
| Immunotherapy | 2 | 2014 | 3535 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2022 | 198 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 172 | 0.050 |
Why?
|
| European Union | 1 | 2021 | 18 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 7934 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2020 | 2851 | 0.050 |
Why?
|
| Drug Industry | 1 | 2021 | 89 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2021 | 140 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 164 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 2294 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 276 | 0.040 |
Why?
|
| International Cooperation | 1 | 2021 | 324 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 329 | 0.040 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 230 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 335 | 0.040 |
Why?
|
| Reoperation | 1 | 2024 | 1389 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 60 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2011 | 9304 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 175 | 0.040 |
Why?
|
| United States | 3 | 2022 | 15994 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 5566 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 817 | 0.040 |
Why?
|
| Codon, Nonsense | 1 | 2018 | 157 | 0.040 |
Why?
|
| Social Class | 1 | 2019 | 321 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 879 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2018 | 145 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1848 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 1113 | 0.040 |
Why?
|
| Endosonography | 1 | 2020 | 549 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1069 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 624 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2019 | 612 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 629 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2020 | 519 | 0.030 |
Why?
|
| Appendectomy | 1 | 2017 | 127 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2018 | 449 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2020 | 1043 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2024 | 1669 | 0.030 |
Why?
|
| Cancer Survivors | 1 | 2023 | 742 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 1031 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 7927 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 2083 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2017 | 282 | 0.030 |
Why?
|
| Colectomy | 1 | 2017 | 290 | 0.030 |
Why?
|
| Appendicitis | 1 | 2017 | 172 | 0.030 |
Why?
|
| Ovary | 1 | 2018 | 701 | 0.030 |
Why?
|
| Global Health | 1 | 2019 | 691 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 315 | 0.030 |
Why?
|
| Karyotyping | 1 | 2016 | 1064 | 0.030 |
Why?
|
| Everolimus | 1 | 2016 | 438 | 0.030 |
Why?
|
| Hyperammonemia | 1 | 2014 | 67 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 357 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2014 | 191 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 823 | 0.030 |
Why?
|
| Muscular Diseases | 1 | 2014 | 163 | 0.030 |
Why?
|
| Epigenomics | 1 | 2014 | 267 | 0.030 |
Why?
|
| Pediatrics | 1 | 2021 | 1178 | 0.020 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2014 | 562 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 414 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 2347 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 1571 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 5037 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 560 | 0.020 |
Why?
|
| Echocardiography | 1 | 2014 | 1240 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2014 | 1032 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2023 | 5687 | 0.020 |
Why?
|
| Animals | 1 | 2012 | 62749 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 5325 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 3661 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 3653 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 4495 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 2123 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 6452 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2014 | 4190 | 0.010 |
Why?
|
| Biomarkers | 1 | 2014 | 5105 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5437 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2014 | 7291 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 14854 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 16188 | 0.010 |
Why?
|
| Middle Aged | 2 | 2014 | 90054 | 0.010 |
Why?
|